BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 3932603)

  • 1. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chemotherapy of epithelial ovarian carcinoma].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy of ovarian cancer.
    Ozols RF; Young RC
    Semin Oncol; 1984 Sep; 11(3):251-63. PubMed ID: 6435250
    [No Abstract]   [Full Text] [Related]  

  • 4. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 5. Altretamine.
    Hansen LA; Hughes TE
    DICP; 1991 Feb; 25(2):146-52. PubMed ID: 1905441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy in advanced forms of carcinoma of the ovary].
    Calciati A; Clerico M; Donadio M; Giaccone G
    Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapeutic management of ovarian cancer.
    Dembo AJ
    Semin Oncol; 1984 Sep; 11(3):238-50. PubMed ID: 6435249
    [No Abstract]   [Full Text] [Related]  

  • 8. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy for advanced ovarian cancer.
    Lucas WE; Markman M; Howell SB
    Am J Obstet Gynecol; 1985 Jun; 152(4):474-8. PubMed ID: 3925784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
    [No Abstract]   [Full Text] [Related]  

  • 12. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
    Levin L; Hryniuk W
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexamethylmelamine (altretamine): early National Cancer Institute trials.
    Young RC
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():31-5. PubMed ID: 1904307
    [No Abstract]   [Full Text] [Related]  

  • 16. [Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].
    Chylak V; Kolarić K; Krusić J
    Lijec Vjesn; 1987 Jun; 109(6):230-4. PubMed ID: 3309515
    [No Abstract]   [Full Text] [Related]  

  • 17. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The potentials of combined chemotherapy in disseminated ovarian cancer].
    Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
    Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
    [No Abstract]   [Full Text] [Related]  

  • 20. Ovarian cancer: what is poor prognosis disease?
    Cohen MH
    J Clin Oncol; 1990 Jul; 8(7):1287-8. PubMed ID: 2113572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.